Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Bio CEO & investor conference

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Feb 07, 2020 2:11pm

122 Views

Post# 30659517

RE:RE:RE:Bio CEO & investor conference

Yawn, dumb and dumber propping each other up as usual.

only a few days to the same old same old. Of course they don't have any money coming in so almost time to dump shares onto the market again. Down, down, down she goes.

realstocky wrote:

100% agreed...they have something good to announce:

marcjohnson wrote:

Interesting, operational update, we just had one not too long ago... if they make a conference out of it, it's good!

stockbuphoon wrote: LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 6, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the BIO CEO & Investor Conference taking place February 10-11, 2020 in New York, USA. The presentation will take place on Monday, February 10^th at 10:15 AM (EST).